Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Statin Adverse Reaction Clear all
Terminated Phase 2 Interventional Results available

STOP Heart Disease in Breast Cancer Survivors Trial

NCT02674204
View directory record Official record
Conditions
Breast Cancer, Heart Disease, Cardiotoxicity, Myocardial Dysfunction
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Jul 22, 2026, 3:45 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant

NCT02988115
View directory record Official record
Conditions
Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, Statin Adverse Reaction
Interventions
bempedoic acid, placebo
Drug · Other
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
52
States / cities
Gilbert, Arizona • Anaheim, California • Long Beach, California + 47 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Jul 22, 2026, 3:45 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo

NCT02993406
View directory record Official record
Conditions
Cardiovascular Diseases, Statin Adverse Reaction
Interventions
Bempedoic acid 180 mg tablet, Matching placebo tablet
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
13,970 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
304
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 246 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Jul 22, 2026, 3:45 AM EDT
Completed Phase 1 Interventional

Statin Therapy to Improve Medication Adherence

NCT01894217
View directory record Official record
Conditions
Hypercholesterolemia, HMG COA Reductase Inhibitor Adverse Reaction
Interventions
Genetic testing and reporting for SLCO1B1*5 allele
Genetic
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 7, 2015 · Synced Jul 22, 2026, 3:45 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)

NCT03001076
View directory record Official record
Conditions
Hypercholesterolemia, Atherosclerosis, Statin Adverse Reaction
Interventions
Bempedoic acid, Ezetimibe, Placebo
Drug · Other
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Georgetown, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2020 · Synced Jul 22, 2026, 3:45 AM EDT
Terminated Phase 4 Interventional Results available

Quality of Life in Patients With Statin-Associated Myopathy

NCT00850460
View directory record Official record
Conditions
Statin Adverse Reaction
Interventions
Statins, Placebo
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
40 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 6, 2016 · Synced Jul 22, 2026, 3:45 AM EDT
Terminated Phase 4 Interventional Results available

7T Magnetic Resonance Spectroscopy and Skeletal Muscle Biopsy Findings in Statin Associated Adverse Muscle Events

NCT04507373
View directory record Official record
Conditions
Muscle Cramp, Ache, Weakness, Muscle, Statin Adverse Reaction
Interventions
Simvastatin 40mg
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Jul 22, 2026, 3:45 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

NIRS to Diagnose SAMS

NCT03653663
View directory record Official record
Conditions
Statin Adverse Reaction, Skeletal Myopathy
Interventions
Simvastatin 20 mg, Placebo Oral Tablet
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
Hartford, Connecticut • Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Jul 22, 2026, 3:45 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms

NCT01032993
View directory record Official record
Conditions
Pain, Weakness, Cramps, Myalgia or Myositis Nos, HMG COA Reductase Inhibitor Adverse Reaction
Interventions
Coenzyme Q10, Placebo
Dietary Supplement · Other
Lead sponsor
Catherine Buettner
Other
Eligibility
21 Years and older
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2017 · Synced Jul 22, 2026, 3:45 AM EDT
Completed Not applicable Interventional Results available

Evaluation of Ubiquinol on Mitochondrial Oxidative Capacity in Statin Patients Using 31PMRS

NCT01702987
View directory record Official record
Conditions
Myopathy, HMG COA Reductase Inhibitor Adverse Reaction, Hypercholesterolemia
Interventions
ubiquinol, placebo, statin
Dietary Supplement · Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 16, 2017 · Synced Jul 22, 2026, 3:45 AM EDT
Recruiting Phase 2 Interventional

Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted

NCT05559164
View directory record Official record
Conditions
Cardiac Toxicity, Early-stage Breast Cancer
Interventions
Lipitor 40mg Tablet
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Elizabeth, New Jersey • Hamilton, New Jersey • Jersey City, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Jul 22, 2026, 3:45 AM EDT
Recruiting Phase 1 Interventional

Safety and Efficacy of LOw DOse COlchicine in Patients With STatin INTolerance: the LODOCO STINT Pilot Study

NCT06874192
View directory record Official record
Conditions
Statin Adverse Reaction
Interventions
Low-dose colchicine at 0.5mg daily, Placebo
Drug · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 22, 2026, 3:45 AM EDT
Completed Not applicable Interventional Results available

Genetically Guided Statin Therapy

NCT01894230
View directory record Official record
Conditions
Hypercholesterolemia, Hydroxy-methylglutaryl-coenzyme A (HMG Co-A) Reductase Inhibitors Adverse Reaction
Interventions
SLCO1B1*5 allele testing, results reported at randomization, SLCO1B1*5 allele testing, results reported at end of study, Genetic testing for SLCO1B1*5 allele
Genetic
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Travis Air Force Base, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Jul 22, 2026, 3:45 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

The DEtermining Statin Intolerance FOr Rosuvastatin (DESIFOR) Trial

NCT03889314
View directory record Official record
Conditions
Cardiovascular Risk Factor, Cardiovascular Diseases, Adverse Effect
Interventions
Rosuvastatin 20mg, Placebo
Drug · Other
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
21 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 20, 2022 · Synced Jul 22, 2026, 3:45 AM EDT
Completed No phase listed Observational Results available

Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase Inhibitors

NCT04064294
View directory record Official record
Conditions
Parkinson Disease, Dyskinesia, Drug-Induced
Interventions
Intravenous Infusion
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Jul 22, 2026, 3:45 AM EDT
Recruiting Phase 4 Interventional

DESIFOR-EXPAND (MHIF)

NCT06804980
View directory record Official record
Conditions
Statin Therapy, Statin Adverse Reaction, Statin
Interventions
Rosuvastatin (Crestor), Placebo
Drug
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Jul 22, 2026, 3:45 AM EDT